Hormone · Synthetic gonadotrophin-releasing hormone receptor antagonist
Teverelix
Also known as —
A synthetic decapeptide GnRHR antagonist for investigating receptor blockade and pituitary endocrine signalling.
- Length
- 10 amino acids
- Half-life
- Not well characterised
- Mechanism
- Teverelix binds competitively to GnRHR without producing the receptor activation characteristic of GnRH. It inhibits GnRH-evoked signalling, including the phospholipase C–inositol phosphate–calcium pathway in appropriate cellular systems.
- Studied in
- Receptor-binding assays, pituitary-cell systems and animal endocrine models study Teverelix as an inhibitor of GnRH-dependent signalling and gonadotrophin secretion.
About Teverelix
Teverelix is a structurally modified analogue of the endogenous decapeptide GnRH, also known as luteinising hormone-releasing hormone. Its antagonist scaffold contains non-proteinogenic amino acids and D-configured residues, rather than simply reproducing the native hormone sequence. These modifications alter receptor interactions and susceptibility to enzymatic cleavage. Research characterisation centres on competitive GnRHR blockade, with binding measurements and functional signalling assays providing complementary descriptions of its interaction with the receptor.
For this peptide, formulation and salt form deserve particular attention when comparing experimental reports. Counter-ion identity, peptide concentration and the surrounding medium can influence solubility or association behaviour, which may change the fraction available to interact with receptors. Animal endocrine studies also integrate distribution and clearance with receptor pharmacology. Consequently, a prolonged change in circulating gonadotrophins cannot, by itself, establish either intrinsic receptor residence time or a generalisable plasma half-life.
Laboratory notes
- Record the counter-ion and peptide content; total powder mass may include counter-ions and residual water.
- Check solution clarity and peptide recovery in the intended assay buffer before interpreting concentration–response data.
- Keep pre-incubation time consistent and document receptor species, expression level and GnRH challenge conditions.
Storage and reconstitution basics: storage guide.
Questions about Teverelix
Which receptor is the main target?
The principal target is GnRHR, the receptor through which GnRH regulates pituitary gonadotrophin secretion.
Why should the salt form be recorded?
Salt form can affect peptide content calculations and solution behaviour, making it relevant to comparisons between lots and experiments.
Is endocrine response duration equivalent to receptor residence time?
No. Endocrine response duration also reflects exposure, feedback and downstream biology; residence time requires dedicated binding-kinetic experiments.
Is Teverelix for human use?
No. It is supplied strictly for in-vitro laboratory research and is not for human or animal consumption.
Related research peptides
All products are sold for laboratory research use only. Not for human consumption, not a medicine, not for diagnosing, treating or preventing any condition.